Shares of Allergy Therapeutics plc (LON:AGY - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 6.66 ($0.09) and traded as low as GBX 6.50 ($0.09). Allergy Therapeutics shares last traded at GBX 6.77 ($0.09), with a volume of 1,126,674 shares traded.
Allergy Therapeutics Stock Up 4.3%
The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The company's fifty day moving average is GBX 6.89 and its 200-day moving average is GBX 6.66. The company has a market cap of £358.80 million, a PE ratio of -7.04, a PEG ratio of -30.70 and a beta of 1.40.
Allergy Therapeutics (LON:AGY - Get Free Report) last issued its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. On average, analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
